24 completed, 11 terminated, 5 unknown, 4 recruiting. 50 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 50 | Completed 24, Terminated 11, Unknown 5, Recruiting 4, Withdrawn 4, Not yet recruiting 2 |
| Phase 1 | 5 | Completed 3, Recruiting 1, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow LV: new trials by email Literature Review of LV trials Research Report on LV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer Irinotecan Liposome, 5-FU, LV - Metastatic Colorectal Cancer | Phase 2 | Recruiting | West China Hospital | 86 | 2024-06-30 | 2024-08-12 |
| Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV Irinotecan liposoma, oxaliplatin, bevacizumab - Advanced Pancreatic Cancer (Part 1) | Phase 1 / Phase 2 | Recruiting | Dai, Guanghai | 138 | 2024-06-23 | 2025-01-20 |
| Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer Adebrelimab, Oxaliplatin 100 MG, Irinotecan liposome - Pancreatic Cancer | Phase 2 | Unknown | Fudan University | 87 | 2024-06-05 | 2024-08-09 |
| HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer HR070803, Oxaliplatin, Tegafur - Efficacy and Safety | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 120 | 2024-04-20 | 2024-04-25 |
| A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer Fluorouracil, Leucovorin, Oxaliplatin - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Terminated | Baylor College of Medicine | 3 | 2024-03-06 | 2026-04-09 |
| Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX Irinotecan liposome injection, Oxaliplatin, 5-FU - Pancreatic Cancer | Phase 2 | Not yet recruiting | Changhai Hospital | 134 | 2024-02-01 | 2024-01-18 |
| Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer liposomal irinotecan, 5-FU, LV - Colorectal Cancer | Phase 2 | Recruiting | Hebei Medical University Fourth Hospital | 173 | 2024-01-01 | 2024-10-09 |
| AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 AZD0901, 5-Fluorouracil, Leucovorin - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 2 | Recruiting | AstraZeneca | 226 | 2023-12-13 | 2026-09-30 |
| A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer Fosifloxuridine Nafalbenamide, Leucovorin, Irinotecan - Colorectal Cancer, Colorectal Neoplasms | Phase 2 | Terminated | NuCana plc | 180 | 2023-04-18 | 2025-09-12 |
| NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer Irinotecan Liposomal Injection [Onivyde], Capecitabine, 5-fluorouracil - Pancreatic Cancer | Phase 2 | Unknown | Seoul National University Hospital | 200 | 2020-06-23 | 2024-04-19 |
| CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC Bevacizumab, 5-fluorouracil, Leucovorin calcium - Metastatic Colorectal Cancer | Phase 2 | Unknown | Chugai Pharmaceutical | 112 | 2019-10-11 | 2019-10-31 |
| Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer ladiratuzumab vedotin, Pembrolizumab - Triple Negative Breast Neoplasms | Phase 1 / Phase 2 | Completed | Seagen Inc. | 185 | 2018-02-27 | 2025-12-12 |
| Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma nal-IRI, 5 fluorouracil, Leucovorin - Pancreatic Cancer | Phase 2 | Completed | Ipsen | 56 | 2015-10-19 | 2022-10-10 |
| C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer c-Met inhibitor AMG 337, placebo, oxaliplatin - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 / Phase 2 | Withdrawn | Eastern Cooperative Oncology Group | 2015-03-06 | 2023-05-25 | |
| Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer ziv-aflibercept, leucovorin calcium, fluorouracil - Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum | Phase 2 | Withdrawn | University of Southern California | 2015-03-01 | 2015-05-06 | |
| Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer 5-FU, LV, ziv-aflibercept - Colorectal Cancer, Metastatic Colorectal Cancer | Phase 2 | Withdrawn | NSABP Foundation Inc | 2014-11-01 | 2014-12-02 | |
| Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients Raltitrexed, Irinotecan, 5-fluorouracil - Colorectal Carcinoma | Phase 2 | Unknown | Fudan University | 100 | 2014-09-01 | 2015-03-03 |
| Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer 5-Fluorouracil, Leucovorin, Irinotecan - Colon Cancer | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 100 | 2014-05-06 | 2025-05-18 |
| Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer oxaliplatin, leucovorin calcium, irinotecan hydrochloride - Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas | Phase 2 | Completed | Yale University | 46 | 2014-03-25 | 2026-03-06 |
| FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma oxaliplatin, leucovorin calcium, fluorouracil - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 2 | Unknown | Case Comprehensive Cancer Center | 63 | 2014-02-10 | 2024-01-08 |
Showing 20 of 50. Sign in to see all of them.
Colorectal Neoplasms (11) · Colonic Neoplasms (10) · Rectal Neoplasms (9) · Stomach Neoplasms (9) · Pancreatic Neoplasms (7) · Adenocarcinoma Of Esophagus (4) · Esophageal Neoplasms (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Osteosarcoma (2) · Bile Duct Neoplasms (1) · Biliary Tract Neoplasms (1) · Blast Crisis (1) · Breast Neoplasms (1) · Burkitt Lymphoma (1) · Carcinoma, Hepatocellular (1)
National Cancer Institute (NCI) (8) · Case Comprehensive Cancer Center (2) · Children's Oncology Group (2) · City of Hope Medical Center (2) · Fudan University (2) · John Hays (2) · Roswell Park Cancer Institute (2) · University Hospital of Crete (2) · University of Southern California (2) · AstraZeneca (1) · BTG International Inc. (1) · Baylor College of Medicine (1) · Changhai Hospital (1) · Chugai Pharmaceutical (1) · Dai, Guanghai (1)
United States (34) · China (8) · Australia (4) · Spain (4) · Canada (3) · Greece (3) · South Korea (3) · Germany (2) · Japan (2) · Puerto Rico (2) · United Kingdom (2) · France (1) · Georgia (1) · Italy (1) · Malaysia (1)
Afsaneh Barzi (2) · John Hays, MD (2) · Akihito Tsuji, M.D., Ph.D. (1) · Allyson Ocean (1) · Aref Al-Kali, M.D. (1) · Crystal Denlinger (1) · David Bajor, MD (1) · David Ebb (1) · David I. Rosenthal, MD (1) · Deirdre Cohen (1) · Do-Youn Oh, M.D., PhD. (1) · Elisabeth Oelmann, MD, PhD (1) · Elizabeth Raetz, MD (1) · Guiying Wang, Professor (1) · Hanna Sannoff, MD (1)
PMID 21208843, PMID 23293700, PMID 24077846, PMID 27913881, PMID 28419486, PMID 30117142, PMID 30525443, PMID 30957229, PMID 32154021, PMID 32649004, PMID 32703200, PMID 33957442, PMID 34019214, PMID 34162404, PMID 34750990, PMID 38900452, PMID 38901425
U10CA098543 (4), N01CM00070 (2), P30CA014089 (2), 2015 (1), 2017 (1), N01CM00038 (1), N01CM00071 (1), N01CM62201 (1), N01CM62204 (1), P01CA043904 (1), P30CA006927 (1), P30CA016087 (1), P30CA016359 (1), U01CA062502 (1), U10CA021115 (1)